Dashyant Dhanak - Net Worth and Insider Trading
Dashyant Dhanak Net Worth
The estimated net worth of Dashyant Dhanak is at least $4 Million dollars as of 2023-03-28. Dashyant Dhanak is the EVP & Chief Scientific Officer of Incyte Corp and owns about 53,263 shares of Incyte Corp (INCY) stock worth over $4 Million. Details can be seen in Dashyant Dhanak's Latest Holdings Summary section.
Transaction Summary of Dashyant Dhanak
Dashyant Dhanak Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Dashyant Dhanak owns 1 companies in total, including Incyte Corp (INCY) .
Click here to see the complete history of Dashyant Dhanak’s form 4 insider trades.
Insider Ownership Summary of Dashyant Dhanak
|Ticker||Comapny||Transaction Date||Type of Owner|
|INCY||Incyte Corp||2018-12-10||EVP & Chief Scientific Officer|
Dashyant Dhanak Latest Holdings Summary
Dashyant Dhanak currently owns a total of 1 stock. Dashyant Dhanak owns 53,263 shares of Incyte Corp (INCY) as of January 26, 2023, with a value of $4 Million.
Latest Holdings of Dashyant Dhanak
|Ticker||Comapny||Latest Transaction Date||Shares Owned||Current Price ($)||Current Value ($)|
Holding Weightings of Dashyant Dhanak
Dashyant Dhanak Form 4 Trading Tracker
According to the SEC Form 4 filings, Dashyant Dhanak has made a total of 15 transactions in Incyte Corp (INCY) over the past 5 years, including 0 buys and 15 sells. The most-recent trade in Incyte Corp is the sale of 2,419 shares on January 26, 2023, which brought Dashyant Dhanak around $205,615.
Insider Trading History of Dashyant Dhanak
Dashyant Dhanak Trading Performance
Dashyant Dhanak Ownership Network
Ownership Network List of Dashyant Dhanak
Ownership Network Relation of Dashyant Dhanak
Dashyant Dhanak Owned Company Details
What does Incyte Corp do?
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Who are the key executives at Incyte Corp?
Dashyant Dhanak is the EVP & Chief Scientific Officer of Incyte Corp. Other key executives at Incyte Corp include Principal Accounting Officer Thomas Tray , EVP & Head of Tech. Operations Michael James Morrissey , and EVP & General Manager & Europe Jonathan Elliott Dickinson .
Incyte Corp (INCY) Insider Trades Summary
Over the past 18 months, Dashyant Dhanak made 2 insider transaction in Incyte Corp (INCY) with a net sale of 2,808. Other recent insider transactions involving Incyte Corp (INCY) include a net purchase of 2,510,403 shares made by Baker Bros. Advisors Lp , a net sale of 30,111 shares made by Vijay K Iyengar , and a net sale of 46,866 shares made by Barry P Flannelly .
In summary, during the past 3 months, insiders sold 97,842 shares of Incyte Corp (INCY) in total and bought 0 shares, with a net sale of 97,842 shares. During the past 18 months, 209,240 shares of Incyte Corp (INCY) were sold and 2,510,403 shares were bought by its insiders, resulting in a net purchase of 2,301,163 shares.
Incyte Corp (INCY)'s detailed insider trading history can be found in Insider Trading Tracker table.
Incyte Corp Insider Transactions
Dashyant Dhanak Mailing Address
Above is the net worth, insider trading, and ownership report for Dashyant Dhanak. You might contact Dashyant Dhanak via mailing address: C/o Incyte Corporation, 1801 Augustine Cut-off, Wilmington De 19803.